Mainz, December, 2018 – TRON is proud to have taken part in the research that lead to this publication in OncoImmunology.
This publication - in collaboration with scientists from BioNTech, DKFZ, JPT, and the University Medicine Mainz - points to hurdles on our way to highly personalized cancer immunotherapy. The research group investigated neoepitope-specific CD8+ T-cell responses - either spontaneously or after immunotherapy regimens - which induce local tumor inflammation and cell death. Surprisingly, even though all tested treatment regimens were found to induce a single significant CD8+ T-cell response, neither neoepitope-specific T cells nor their T cell receptors (TCRs) were able to recognize or lyse tumor cells. Hence, the publication concludes that neoepitope specific CD8+ T cells primed by tumor-released antigen exposure can be functionally irrelevant.
Mainz, December 20, 2018 – TRON is delighted to announce an article published in Nature.
Working with GAPVAC (Glioma Actively Personalized Vaccine Consortium), TRON participated in developing a highly personalized approach to the treatment of glioblastoma. The consortium publish data on the results of a phase 1 multi-center, multi-national clinical trial, showing favorable safety and immune response results.
Read more about the trial here.
Read more about GAPVAC here.
Mainz, November 27, 2018 – TRON is delighted to announce an article published in Chemical Society Reviews co-authored by Mustafa Diken.
In collaboration with a European team of scientists working on nanomaterials in medicine, Dr. Diken provides an overview of the current state-of-the-art concerning nano- and macroscale materials and their application in immunotherapy. Covering current applications, challenges and future directions, this review offers a concise review of materials science in immuno-oncology today.
Verona, September 27, 2018 – The Macrophage and Dendritic Cell Society is holding its 32nd annual meeting 27-29 September in beautiful Verona, Italy. This year’s theme is “the crossroad between macrophage and dendritic cells: from immunometabolism to single cell fate.” In this context, TRON’s Mustafa Diken is giving today’s Happy Hour Lecture, entitled “Bringing the message to dendritic cells with mRNA.”
Mainz, September 2018 - TRON is proudly hosting a scholar from the Zoran Djindjic Program (ZDS). Created in 2003 after the assassination of the first democratically elected Prime Minister of Serbia, and supported by the German federal government, the aim of the program is to provide short internships in German institutions for highly qualified candidates from the West Balkans (Albania, Bosnia and Herzegovina, Macedonia, Montenegro, Kosovo, Croatia and Serbia). TRON’s student, Marijana Slijepčević, has written a blog about her ZDS experiences, which we invite you to read here.
Mainz, September 2018 - TRON is sponsoring two scholarships in the Deutschlandstipendium 2018/2019 of the Johannes Gutenberg University Mainz, thereby supporting two young medical students as part of this Federal Ministry of Education and Research program. Scholarship holders were selected based on proven excellence, exceptional social commitment, and special social or family circumstances.
TRON in the Media
Welcome to TRON
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.